Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. This quarter, three novel monoclonal antibody drugs have been approved by China.
Antibody research is increasingly supported by computational methods, such as structure prediction methods and molecular dynamics (MD) simulations, particularly to look at behavior over time under a defined set of simulation conditions. In recent literature, MD is being used less as a standalone technique and more as part of broader workflows that combine structure modeling, feature extraction, machine learning, and experimental characterization.
Multiple myeloma (MM) treatment is increasingly shaped by antibody-based approaches, with monoclonal antibodies being redesigned, and newer formats (bispecifics, trispecifics, ADCs), expanding what antibodies can actually do in patients.
Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228
Time: April 17 – 22, 2026
Location: San Diego, CA
Booth: #4154
Time: April 28 – 30, 2026
Location: Seoul, South Korea
Booth: #B31
Watch our webinar on accelerating antibody discoveru. Single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.
During the NextGen Biomed 2026 conference in London, Lei Shi, PhD, Senior Vice President of Biointron, discussed Biointron's unique single B cell sorting-based antibody discovery process integrated with our high-throughput expression, validation and developability platforms.
Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Join Biointron’s Google Review & Reward Program! Share your experience on Biointron google profile and earn a $25 gift card as reward!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in March, we'll highlight antibody allostery, trends in developability, and anti-IgE therapeutics.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in February, we'll highlight radioantibodies, antibody-cytokine fusion proteins, and conditionally active antibodies.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in January, we'll do a deep dive into last year's novel antibody drugs, G protein-coupled receptors, and fusion proteins.
A new generation of biotech companies is rapidly advancing the antibody landscape, fueled by strong early-stage funding and a focus on differentiated therapeutic strategies. Across modalities, from bispecific antibodies and ADCs to single-domain antibodies, shuttle systems, and half-life extension, these emerging players are not only expanding the scope of what antibodies can target, but also how they function in complex disease settings.
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and autoimmune applications, alongside advancements in targeted protein degradation.
Clinical drug development remains associated with a high failure rate, primarily to lack of efficacy, unmanageable toxicity, and suboptimal drug-like properties. These data indicate that, despite extensive optimization workflows, current strategies do not fully capture all determinants of clinical success.
You can also contact us on the Scientist and Science Exchange marketplaces.
